Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
October 2022
Signaux de toxicité associés au sécukinumab : Une étude de pharmacovigilance basée sur la base de données du système de notification des effets indésirables de la Food And Drug Administration des États-Unis
Br J Clin Pharmacol. 2022 doi: 10.1111/bcp.15535
This study explored the clinical characteristics, outcomes, and time to onset of the four main toxicities of secukinumab with hypersensitivity identified as the most common toxicity.
Keywords:
February 2018
Tofacitinib avec les Antirhumatismaux Modificateurs de la Maladie Conventionnels chez les Patients d’origine Chinoise avec une Polyarthrite Rhumatoïde : Résultats Rapportés par les Patients d’un Essai Randomisé Contrôlé de Phase 3
Int J Rheum Dis 2018; 21(2):402–14
This Chinese sub-population of patients with RA from ORAL Sync reported significant improvements in patient-reported outcomes (PROs), which were maintained up to 12 months from tofacitinib (TOF) treatment initiation. ORAL Sync was a randomised, Phase 3 study investigating TOF therapy in combination with csDMARDs in patients with active RA who had previously had an inadequate response to csDMARDs. To date, this is the only Phase 3 study of TOF in patients from China with RA. This analysis include...